Dai Kurihara has extensive experience in research planning, non-clinical studies, and regulatory affairs within both Japanese and American pharmaceutical companies, covering the drug development process from the early discovery stages to obtaining marketing authorization. His work spans a wide range of modalities and diverse therapeutic areas, including oncology, immunology, infectious diseases, and cardiovascular diseases. Additionally, he serves in an advisory role to a startup and supports the social implementation of academic innovation.
He earned his Ph.D. in Medicine from Osaka University Graduate School of Medicine and his Master of Business Administration from Globis University Graduate School of Management.